Dentsply Sirona Explores Strategic Options for Wellspect Healthcare Business
Charlotte, N.C., February 11, 2025 – Dentsply Sirona Inc. (Nasdaq: XRAY), a global leader in dental products and technology, announced that it has begun evaluating strategic alternatives for its Wellspect Healthcare business, a prominent provider in bladder and bowel management solutions.
Overview of Wellspect Healthcare
Wellspect Healthcare boasts over 40 years of experience in the continence care market. The company offers a broad portfolio of products and accessories from well-known brands such as LoFric® and Navina™, which have contributed to strong organic sales growth in recent years. Wellspect achieved mid- to high-single-digit growth in 2023 and maintained this momentum through the first three quarters of 2024.
The continence care market is significant and expanding, with an estimated total addressable market value of about $2 billion. Wellspect’s established product lines and innovation pipeline position it well to capitalize on this growth potential.
Leadership Comments on Strategic Review
Simon Campion, President and CEO of Dentsply Sirona, emphasized that the strategic review aims to unlock meaningful value for all stakeholders. He noted how the company had previously invested in enhancing Wellspect’s foundation through product innovation, capacity expansion, and profitable revenue growth to better meet rising demand.
Campion highlighted ongoing development of a strong product pipeline and efforts to access new and untapped markets, both within Wellspect’s core offerings and related adjacent areas. Early indicators suggest that this strategic focus has already resulted in improved financial performance for the business.
“This process allows us to identify the best future pathway for Wellspect that supports its accelerated growth and success,” Campion said. “Simultaneously, this will enable Dentsply Sirona to sharpen its focus on the dental business, where we see significant opportunities for innovation and expansion.”
Continuing Business Transformation
Campion also provided updates on Dentsply Sirona’s broader transformation strategy. The company is actively working on reshaping its organization to drive operational efficiencies, enhance customer engagement, and allocate resources more strategically, especially within commercial investments.
“We are confident that these initiatives will enable us to fully realize the potential of our broad-based dental platform,” he stated. The company remains committed to ongoing disciplined portfolio evaluation, cost structure optimization, and investment decisions aimed at sustainable and profitable growth with enhanced shareholder returns.
Process Timeline and Advisors
At this stage, there is no set deadline or guaranteed outcome for the exploration of strategic alternatives regarding Wellspect. Dentsply Sirona does not plan to disclose further updates unless the Board approves a definitive course of action or finds it necessary to provide additional information.
Goldman Sachs & Co. LLC serves as the financial advisor, while legal counsel is provided by Wachtell, Lipton, Rosen & Katz.
Upcoming Financial Reporting
Dentsply Sirona reiterated its plan to report full-year and fourth-quarter 2024 financial results on February 27, 2025, and to host a corresponding investor conference call.
About Dentsply Sirona
With more than a century of innovation, Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies. The company designs, manufactures, and markets a wide-ranging portfolio that includes dental and oral health products alongside other consumable medical devices under globally recognized brands.
Headquartered in Charlotte, North Carolina, Dentsply Sirona is publicly traded on Nasdaq under the ticker symbol XRAY. The company focuses on delivering innovative and high-quality solutions aimed at enhancing patient care and advancing safer dental procedures worldwide.
Forward-Looking Statements and Risk Factors
This press release includes forward-looking statements concerning the potential outcomes of the Wellspect strategic review, including whether a transaction will result and the terms or timing involved. Such statements represent current expectations but are subject to risks, uncertainties, and factors outside company control that could cause actual results to differ materially.
Investors are cautioned not to place undue reliance on these statements. Factors that may impact actual outcomes include competitive market conditions, the success of product differentiation and innovation efforts, regulatory approvals, cost control effectiveness, distribution channel dynamics, and broader industry trends. The company undertakes no obligation to update these statements publicly in response to future developments unless legally required.
Contact Information
Investor Relations: Andrea Daley
Vice President, Investor Relations
Phone: +1-704-591-8631
Email: [email protected]
Public Relations: Marion Par-Weixlberger
Vice President, Public Relations & Corporate Communications
Phone: +43 676 848414588
Email: [email protected]
This announcement underscores Dentsply Sirona’s proactive approach to portfolio management and focus on creating long-term value through strategic business realignment and transformation.